Document is current
Any future updates will be listed below
-
Authors
Sanchez, R.
Duncker, D.
Colley, B.
Doering, M.
Gummadi, S.
Perings, C.
Robertson, M.
Shroff, G.
Veltmann, C. https://orcid.org/0000-0001-7587-1124
,
- License Information
-
More Information
Article History
Accepted: 20 December 2022
First Online: 25 January 2023
Change Date: 14 February 2023
Change Type: Erratum
Change Details: An Erratum to this paper has been published:
Change Details: https://doi.org/10.1007/s00399-023-00928-5
Declarations
:
: B. Colley: Honoraria for lectures or consulting from Abbott and Medtronic. C. Perings: Honoraria for lectures or consulting from Bayer, Boehringer Ingelheim, Zoll. C. Veltmann: Honoraria for lectures or consulting from Abbott, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, CVRx, Medtronic, Pfizer, and Zoll. D. Duncker: Honoraria for lectures, travel grants and/or a fellowship grant from Abbott, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CVRx, Medtronic, Microport, Pfizer, Zoll. R. Sanchez, M. Doering, S. Gummadi, M. Robertson, G. Shroff, and Heart Failure Optimization Study (HF-OPT) Investigators declare that they have no competing interests.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hannover Medical School (No.: 7292) and by the ethics committee by each participating center. Clinical trial registration: NCT03016754. All patients gave written informed consent to HF-OPT.
